Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

Journal of the Neurological Sciences

Volumn 215, Issue 1-2, 2003, Pages 37-44

  Chen, Man ^b   Valenzuela, Reuben Mari ^b   Dhib Jalbut, Suhayl ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

BDNF; Copaxone ; Glatiramer acetate; Multiple sclerosis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 5;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0142074862     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00177-1     Document Type: Article

References (32)

1. Sela M., Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother. 2(7):2001;1149-1165.
2. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P.et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 45(7):1995;1268-1276.
3. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P.et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 57(12 Suppl. 5):2001;S46-S53. [1998, classical article].
4. Wolinsky J.S., Narayana P.A., Johnson K.P. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult. Scler. 7(1):2001;33-41.
5. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S.et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 92(1-2):1998;113-121.
6. Neuhaus O., Farina C., Wekerle H., Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 56(6):2001;702-708.
7. Gran B., Tranquill L.R., Chen M., Bielekova B., Zhou W., Dhib-Jalbut S. et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 55(11):2000;1704-1714.
8. Qin Y., Zhang D.Q., Prat A., Pouly S., Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J. Neuroimmunol. 108(1-2):2000;201-206.
9. Chen M., Gran B., Costello K., Johnson K., Martin R., Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler. 7(4):2001;209-219.
10. Dabbert D., Rosner S., Kramer M., Scholl U., Tumani H., Mader M.et al. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci. Lett. 289(3):2000;205-208.
11. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105(7):2000;967-976.
12. Ragheb S., Abramczyk S., Lisak D., Lisak R. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Mult. Scler. 7(1):2001;43-47.
13. Aharoni R., Teitelbaum D., Leitner O., Meshorer A., Sela M., Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 97(21):2000;11472-11477.
14. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 58(8 Suppl. 4):2002;S3-S9.
15. Filippi M., Rovaris M., Rocca M.A., Sormani M.P., Wolinsky J.S., Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes" Neurology. 57(4):2001;731-733.
16. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M.et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U. S. A. 97(13):2000;7446-7451.
17. Schori H., Kipnis J., Yoles E., WoldeMussie E., Ruiz G., Wheeler L.A.et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl. Acad. Sci. U. S. A. 98(6):2001;3398-3403.
18. Kipnis J., Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol. Med. 8(7):2002;319-323.
19. Ziemssen T., Kumpfel T., Klinkert W.E.F., Neuhaus O., Hohlfeld R. Glatiramer acetate-specific T-helper 1 and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain. 125:2002;2381-2391.
20. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 125(Pt 1):2002;75-85.
21. Kerschensteiner M., Gallmeier E., Behrens L., Leal V.V., Misgeld T., Klinkert W.E.et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189(5):1999;865-870.
22. Makar T.K., Wilt S., Dong Z., Fishman P., Mouradian M.M., Dhib-Jalbut S. IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system. J. Interferon Cytokine Res. 22(7):2002;783-791.
23. McTigue D.M., Horner P.J., Stokes B.T., Gage F.H. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci. 18(14):1998;5354-5365.
24. Neumann H., Misgeld T., Matsumuro K., Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc. Natl. Acad. Sci. U. S. A. 95(10):1998; 5779-5784.
25. Wei R., Jonakait G.M. Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia. J. Neuroimmunol. 95(1-2):1999;8-18.
26. Yan Q., Elliott J., Snider W.D. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature. 360(6406):1992;753-755.
27. Gravel C., Gotz R., Lorrain A., Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat. Med. 3(7):1997;765-770.
28. Kobayashi N.R., Fan D.P., Giehl K.M., Bedard A.M., Wiegand S.J., Tetzlaff W. BDNF and NT-4/5 prevent atrophy of rat rubrospinal neurons after cervical axotomy, stimulate GAP-43 and Talpha1-tubulin mRNA expression, and promote axonal regeneration. J. Neurosci. 17(24):1997;9583-9595.
29. Mitsumoto H., Ikeda K., Holmlund T., Greene T., Cedarbaum J.M., Wong V. et al. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. 36(2):1994;142-148.
30. Levivier M., Przedborski S., Bencsics C., Kang U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15(12):1995;7810-7820.
31. Kim D.H., Gutin P.H., Noble L.J., Nathan D., Yu J.S., Nockels R.P. Treatment with genetically engineered fibroblasts producing NGF or BDNF can accelerate recovery from traumatic spinal cord injury in the adult rat. Neuroreport. 7(13):1996;2221-2225.
32. Bemelmans A.P., Horellou P., Pradier L., Brunet I., Colin P., Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10(18):1999;2987-2997.